PROFESSIONAL BACKGROUND

Julie Law joined the Section of Pulmonary, Critical Care, Sleep and Allergy in March of 2005. She has coordinated several studies, including a validation study comparing breathing-event detection between clinical polysomnography and the Respironics REMstar Pro M Series continuous positive airway pressure (CPAP) machine, as well as two studies involving trial medications for the treatment of obstructive sleep apnea (OSA). Ms. Law will coordinate two upcoming studies, one examining the effects of CPAP on glucose control in subjects with type 2 diabetes, and the other investigating the use of a new drug treatment for OSA. As a Research Specialist, Ms. Law recruits, screens, and follows subjects through all phases of a clinical trial, and in the process makes it a priority to get to know her subjects personally. She strives to put her subjects at ease by patiently addressing all their concerns and assisting them if they plan on seeking treatment following their study participation. Before coming to UIC, she coordinated clinical trials investigating new drug treatments for lung cancer at Northwestern University's Robert H. Lurie Comprehensive Cancer Center, and prior to that assisted with Alzheimer's research studies at the Rush Alzheimer's Disease Center and the Chicago Center for Clinical Research (now Radiant Research).

RESEARCH PROJECTS

"Cognitive Behavioral Therapy for Insomnia in People with COPD" (Mary Kapella PI)

“Prediction of Physiological Events in Patients with Sleep Disordered Breathing” (Johnathan Waxman PI)

"Feasibility and Normative Data of the EVL Driving Simulator" (Johnathan Waxman PI)

"Effect of CPAP on glucose control in minority type 2 diabetics" (James Herdegen PI)

"Randomized, double-blind, placebo-controlled study of the safety and efficacy of a new drug treatment in patients with obstructive sleep apnea syndrome" (David Carley PI)

"Validation of breathing event detection of the REMstar Pro II during clinical polysomnography" (James Herdegen PI)

"Pharmacologic treatment of sleep apnea" (David Carley PI)

"A randomized, double-blind, placebo-controlled, multicenter parallel-group dose ranging clinical trial to assess the efficacy and safety of Org 4419-2 in the treatment of obstructive sleep apnea/hypopnea syndrome" (David Carley PI)